Comparing Enhertu vs Ibrance
| Enhertu (fam-trastuzumab deruxtecan) | Ibrance (palbociclib) |
|
|---|
| Enhertu (fam-trastuzumab deruxtecan) | Ibrance (palbociclib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer, Non Small Cell Lung Cancer, Solid Tumors, Gastric Cancer. Enhertu may also be used for purposes not listed in this medication guide. |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Related suggestions Breast Cancer
Popular comparisons
|
|||||||||||||||
| More about Enhertu (fam-trastuzumab deruxtecan) | More about Ibrance (palbociclib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Enhertu has an average rating of 8.0 out of 10 from a total of 30 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 3% reported a negative effect. |
Ibrance has an average rating of 6.8 out of 10 from a total of 85 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Enhertu side effects |
View all Ibrance side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Enhertu prices |
View all Ibrance prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
136.8 hours |
29 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 175 drugs are known to interact with Enhertu:
|
A total of 485 drugs are known to interact with Ibrance:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
February 03, 2015 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.